neostigmine has been researched along with Hyperkinetic Dysphonia in 1 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chandra, A | 1 |
| Pant, B | 1 |
1 other study available for neostigmine and Hyperkinetic Dysphonia
| Article | Year |
|---|---|
Hypophonia as only presenting symptom in myasthenia gravis - a diagnostic dilemma in poor countries: a case report.
Topics: Anti-Inflammatory Agents; Bulbar Palsy, Progressive; Cholinesterase Inhibitors; Dysphonia; Female; H | 2019 |